



Press Release
July 22, 2013

Sale of hepatitis technologies completed

ChronTech has now closed the deal concerning the sale of its hepatitis technologies to the Irish company Avac Pharma Ltd in accordance with the Term Sheet previously published. This means that the Company has received another 625,000 USD, that the earlier loan of 625,000 USD has been assigned, another 1 million USD will be paid within a year, and that Avac Pharma Ltd will pay up to 1.5 million USD for the further development of ChronTechs injection technology IVIN. In accordance with the Term Sheet also 80,274,295 shares have been transferred to ChronTechs certified advisor Remium and the redemption of these shares have been registered with the Swedish Companies Registration Office.

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Mobile phone: +46 709 28 05 28

E-mail: anders.vahlne@chronotech.se

About ChronTech

ChronTech has developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se

In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.